Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention

Journal of Invasive Cardiology

Volumn 14, Issue 8, 2002, Pages 439-442

  Chen, Wai Hong ^a   Lau, Chu Pak ^a   Lau, Yuk Kong ^a   Ng, William ^a   Lee, Pui Yin ^a   Yu, Cheuk Man ^a   Ma, Edmond ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antithrombotic therapy; Coronary angioplasty; Low molecular weight heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN;

ADULT; AGED; ANGINA PECTORIS; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CLINICAL TRIAL; CORONARY STENT; DEATH; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CHINA; COMBINED MODALITY THERAPY; CORONARY ARTERIOSCLEROSIS; ENOXAPARIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE COMPLICATIONS; TIME FACTORS; TREATMENT OUTCOME; WHOLE BLOOD COAGULATION TIME;

EID: 0036678547     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Relation between activated clotting time during angioplasty and abrupt closure
2. Predictors of blood loss and bleeding complications after angioplasty
3. Vascular complications after balloon and new device angioplasty
4. Abrupt vessel closure
5. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
6. Heparin kinetics in venous thrombosis and pulmonary embolism
7. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor
8. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
9. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
10. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial
11. Low-molecular-weight heparins
12. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE" guys finish first
13. Incidence and consequences of periprocedural occlusion
14. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: Clinical findings through hospital discharge
15. Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans
16. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris
17. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A
18. Randomised, placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
19. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
20. Heparin therapy during extracorporeal circulation: I: Problems inherent in existing heparin protocols
21. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer
22. Low-dose heparin for routine coronary angioplasty and stenting
23. Safety of low dose heparin in elective coronary angioplasty
24. A randomised trial of a fixed high dose vs. a weight-adjusted low dose of intravenous heparin during coronary angioplasty
25. Minimal heparinization in coronary angioplasty - How much heparin is really warranted?